Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Genvor IncGNVR · Entity 7842 | Chief Financial Officer | May 18, 2026 | May 26, 2026 |
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Chief Financial Officer | February 15, 2022 | February 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Genvor Inc
Report date May 18, 2026 · Filed May 26, 2026
This filing explicitly reported no securities owned.
Protagonist Therapeutics, Inc
Report date February 15, 2022 · Filed February 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,521 |
Reported balance
After 2022-02-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-02-15 · Grant · Acquired 7,500 · Balance 18,521 F1: Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on February 15, 2023, 2024 and 2025. F2: Includes an aggregate of 635 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.73 · Expires 2032-02-14 | Direct | 45,000 |
Reported balance
After 2022-02-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-02-15 · Grant · Acquired 45,000 · Balance 45,000 F3: The stock option vests in 48 equal monthly installments following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on February 15, 2023, 2024 and 2025.
F2: Includes an aggregate of 635 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2021.
F3: The stock option vests in 48 equal monthly installments following the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2022 Filed Feb 18, 2022 00:26 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $28.73 | $0.00 |
DisclosureSEC source: 0001104659-22-024841 · tm227111-4_4seq1.xml · derivative · entry 2 Kalkofen Donald A. · CIK 0001771066 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2032-02-14 F3 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 00:26 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-024841 · tm227111-4_4seq1.xml · nonDerivative · entry 1 Kalkofen Donald A. · CIK 0001771066 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,521 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on February 15, 2023, 2024 and 2025. F2 · balance_after: Includes an aggregate of 635 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2021. Read SEC document |
| February 26, 2021 Filed Feb 26, 2021 23:29 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $23.57 | $0.00 |
DisclosureSEC source: 0001209191-21-014973 · doc4.xml · derivative · entry 2 Kalkofen Donald A. · CIK 0001771066 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2031-02-25 F3 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| February 26, 2021 Filed Feb 26, 2021 23:29 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-014973 · doc4.xml · nonDerivative · entry 1 Kalkofen Donald A. · CIK 0001771066 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,386 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will become fully vested on February 26, 2024. F2 · balance_after: Includes an aggregate of 1,711 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2020 and September 9, 2020. Read SEC document |
| February 28, 2020 Filed Feb 28, 2020 22:45 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-014090 · doc4.xml · derivative · entry 1 Kalkofen Donald A. · CIK 0001771066 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-02-27 F1 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| December 03, 2019 Filed Dec 3, 2019 23:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | PurchaseCommon Stock | 562 | $5.09 | $2,860.58 |
DisclosureSEC source: 0001209191-19-058800 · doc4.xml · nonDerivative · entry 2 Kalkofen Donald A. · CIK 0001771066 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,175 Read SEC document |
| December 03, 2019 Filed Dec 3, 2019 23:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | PurchaseCommon Stock | 613 | $5.10 | $3,126.30 |
DisclosureSEC source: 0001209191-19-058800 · doc4.xml · nonDerivative · entry 1 Kalkofen Donald A. · CIK 0001771066 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613 Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 23:40 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $10.06 | $0.00 |
DisclosureSEC source: 0001209191-19-034082 · doc4.xml · derivative · entry 1 Kalkofen Donald A. · CIK 0001771066 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-05-30 F1 · derivative.exercise_date: This option vests over a four-year period with 25% of the shares underlying the option vesting on the one-year anniversary of the vesting commencement date of May 28, 2019, and the balance vesting in equal monthly installments over the following 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.